Ipca Laboratories Ltd (IPCALAB) is currently trading at 1,815.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ipca Laboratories is a fully integrated pharmaceutical company manufacturing over 350 formulations and about 80 APIs across 16 Indian manufacturing units, supplying regulated markets and exports to over 100 countries while operating branded divisions and international subsidiaries to commercialize generics and APIs globally. Q1 FY27 consolidated revenue grew ~21% year‑on‑year to INR 2,788 crore, with domestic formulations at INR 1,082 crore (+13%), exports at INR 603 crore (+34%) and API sales at INR 424 crore (+~30%), showing a broad‑based recovery across geographies and product lines for Ipca Laboratories. Profitability improved materially: consolidated EBITDA rose to INR 638 crore with an EBITDA margin of 22.88% for Q1 FY27 versus 18.39% a year ago, driven by operating leverage, lower personnel and manufacturing cost ratios, and selective pricing and currency benefits reported by Ipca Laboratories. Management upgraded FY27 growth guidance to 14–16% and consolidated EBITDA margin guidance to ~23%, while reiterating medium‑term ambition for higher margins as Unichem synergies, regulated‑market filings and biosimilars/mAbs investments scale up, signaling strategic confidence from Ipca Laboratories. Ipca Laboratories is actively investing in biologics and capacity: a new mAbs facility, Wardha API plant (commercial from Feb 2026), Pithampur controlled‑release capacity, and ongoing API plant additions to relieve Ratlam constraints, positioning Ipca Laboratories for regulated‑market launches and higher export volumes.

Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,252.95 and a high of ₹2,039.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ipca Laboratories Ltd has a market capitalization of approximately 46,049.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ipca Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.38 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 46,049.85 Cr, Ipca Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ipca Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 33.38. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The stock jumped after Ipca reported 21% YoY revenue growth, strong profit growth, margin expansion, and upgraded FY27 revenue and EBITDA margin guidance.

The stock surged after Ipca said the USFDA classified its Ratlam API facility as Voluntary Action Indicated (VAI) in the Establishment Inspection Report, which the company described as minimally acceptable CGMP compliance.

Management reported FY26 consolidated revenue of ₹9,646 crore, up 8% year-on-year.

Ipca reported FY26 revenue of ₹9,646 crore, up 8% year-on-year, and an EBITDA margin of 20.5% versus 19.3% in FY25.